Moreover, miR-29b acts to target Akt3 and inhibit angiogenesis and tumor growth by acting as an anti-angiogenesis and anti-tumorigenesis agent through the VEGF and C-myc arrest in BC cells (Li et al., 2017). This evidence concerns the gene VEGFA and breast cancer.